Corona Remedies IPO
- IPO Open Date: 8 December 2025
- IPO Close Date: 10 December 2025
- Issue Size: ₹655.37 crore total.
- Type of Issue: 100% Offer for Sale (OFS) — existing shareholders/promoters are selling shares.
- Number of Shares on Offer: Approximately 61,71,101 equity shares.
- Face Value: ₹10 per share.
- Price Band (Issue Price): ₹1,008 to ₹1,062 per share.
- Lot Size: 14 shares per lot.
- Minimum Investment (for Retail Investors): ₹14,868 (i.e. 14 shares at upper band price).
- Allotment Date (Tentative): 11 December 2025.
- Expected Listing Date on Stock Exchanges (BSE & NSE): 15 December 2025.
Grey Market Premium (GMP)
- As per one set of pre-IPO reports (around 4–5 December 2025), the GMP for Corona Remedies IPO was quoting at ₹365 per share, implying a potential listing price of ~₹1,427 (upper band ₹1,062 + ₹365).
- On a more recent day (closer to IPO launch), GMP was reported around ₹307 per share.
- According to one IPO-review blog, at around IPO subscription time, GMP was “roughly ₹290–₹300,” indicating positive listing expectations.
- Important caveat: GMP reflects grey-market/unofficial demand sentiment. It is not an official indicator of listing price or success — it can be volatile and speculative.
Thus while GMP suggests optimism among pre-IPO speculators, actual listing gains (if any) will depend on formal demand, allotment, and market conditions.
Business and Company (as per IPO filing)
- Corona Remedies is a branded pharmaceutical formulations company — it develops, manufactures, and markets medicines across therapeutic segments including women’s healthcare, cardio-diabetes, pain management, urology, and others.
- The company operates two manufacturing facilities (in Gujarat and Himachal Pradesh), with multiple production lines.
- As of financials for FY24–FY25, the firm reported revenues of ₹1,196 crore and is among faster-growing companies in its peer set within domestic formulations segment.
Because this IPO is a full Offer-for-Sale, the company is not raising fresh capital — existing shareholders are exiting or reducing their stake. That means IPO proceeds go to sellers, not to the company.
What GMP & IPO Structure Suggest
- What GMP suggests: A high GMP (₹290–₹365) indicates strong grey-market interest — many expect listing gains. Given the upper issue price ₹1,062, a GMP of ₹365 implies listing price of ~₹1,427, or ~34% premium.
- Why some investors may like it: The company has solid revenue scale, a diversified product portfolio in chronic health segments (less seasonal demand), and claimed strong growth.
- Risks / What to watch: Because IPO is OFS-only (no fresh capital), the funds go to existing shareholders — the company doesn’t get cash for growth. Also, GMP being unofficial means actual listing price might differ substantially. Regulatory risks (common in pharma), competition, and post-IPO performance of branded drugs matter.
What a Potential Investor Should Consider
The IPO of Corona Remedies appears to attract decent market excitement, reflected in high GMP and a well-recognized pharmaceuticals brand in the domestic market. Given its product mix — with chronic conditions like cardio-diabetes, women’s healthcare, pain management — it may enjoy steadier demand than seasonal or niche drugs.
However, the fact that it’s a full “offer for sale” (i.e. no fresh capital for business expansion) means long-term value creation will depend on how the company performs as a listed entity — new launches, ability to scale, competition, regulatory oversight. GMP-based listing gains can be tempting, but they are not a guarantee.
If you plan to apply, treat this IPO as a speculative play more than a guaranteed long-term growth bet; monitor post-listing performance, and consider your own risk tolerance.